Tuberous sclerosis complex (TSC) is a multisystemic disorder caused by loss-of-function mutations in the TSC1 or TSC2 genes. Its clinical phenotype is heterogenous, but most patients with TSC have epilepsy.
Natus Medical Inc. entered into a definitive agreement to acquire EU-based neurophysiology solution provider Micromed Group SpA. The transaction is expected to close in early 2023, subject to regulatory approvals from the Italian Council of Ministers’ Presidency and the French Ministry of Economy and Finance. Full terms of the transaction have not been disclosed. “The idea behind this acquisition is to provide a single portfolio of neurodiagnostic and neuromonitoring products in the EU and the whole world,” Thomas Sullivan, CEO of Natus Medical, told BioWorld.
A strong clinical association has been observed between epilepsy and the development of depression, however, it is difficult to study individual molecular and cellular mechanisms underlying these comorbidities in animal models. Researchers from Rutgers University have aimed to develop a cell-type-specific monogenic mouse model of epilepsy and depression comorbidities, which could serve as a tool for identifying disease mechanisms as well as for target and drug screening.
Researchers from Praxis Precision Medicines Inc. presented the discovery and preclinical evaluation of a novel voltage-gated sodium channel (Nav) blocker, PRAX-628, being developed as a potential antiepileptic drug candidate.
A research team based at the University of California, San Diego presented data from a study that evaluated the novel cyclophilin D (CypD) inhibitor CC-2055 in preclinical models of epilepsy.
As Wall Street waits to find out later this year whether Stoke Therapeutics Inc.’s positive results with a low, single dose of STK-001 for Dravet syndrome pans out in more extensive research, a number of players large and small are investigating candidates for the rare but dismal form of epilepsy.
Emory University and Medical College of Wisconsin have presented quinazolinone derivatives acting as NADPH oxidase (NOX) inhibitors reported to be useful for the treatment of traumatic brain injury and epilepsy.
By pairing the expression of an inhibitory ion channel with an activity-dependent promoter, researchers have developed the first on-demand gene therapy that specifically silenced hyperactive cells and prevented epileptic seizures.
